Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide
- 17 November 2005
- journal article
- Published by Elsevier BV in Clinical Immunology
- Vol. 118 (2-3), 180-187
- https://doi.org/10.1016/j.clim.2005.09.014
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- In vitro inhibition of SARS virus replication by human interferonsScandinavian Journal of Infectious Diseases, 2004
- Inhibition of human herpes simplex virus type 2 by interferon γ and tumor necrosis factor α is mediated by indoleamine 2,3-dioxygenaseMicrobes and Infection, 2004
- The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challengesJournal of Clinical Virology, 2004
- TLR9 signals after translocating from the ER to CpG DNA in the lysosomeNature Immunology, 2004
- Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activitiesEuropean Journal of Immunology, 2003
- An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 responseJournal of General Virology, 2003
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretionJournal of Allergy and Clinical Immunology, 2001
- Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cellsEuropean Journal of Immunology, 2001
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995